Scotland Registry for Ankylosing Spondylitis (SIRAS)

Scotland Registry for Ankylosing Spondylitis (SIRAS)

Duration: Data collection (2010 - 2018) (analysis until 2022)
Funders: Pfizer AbbVie
Chief investigator: Professor Gary Macfarlane
Deputy chief investigator: Professor Gareth Jones

The Scotland Registry for Ankylosing Spondylitis (SIRAS) attempted to recruit all patients with ankylosing spondylitis managed in NHS rheumatology departments in Scotland.  Between October 2010 and October 2013, over 2,000 patients with a clinical diagnosis of ankylosing spondylitis (AS) were recruited to the registry from rheumatology departments across Scotland. Clinical data was obtained through audits of patients’ medical records, and patient‐reported information was collected from around half of study participants by postal questionnaire, covering information on general health, pain, function, quality of life and fatigue. Since then, participants who consented to follow‐up have received questionnaires one years and two years after baseline.   A further follow‐up in 2016 collected longer‐term follow‐up data on a number of disease outcomes, such as quality of life and occupational characteristics, as well as new data on disease flares, periodontal disease and the presence of comorbid fibromyalgia. Analysis from registry data remained ongoing, with the latest publication to come from this work in 2022.


What results has the study produced?

The following publications draw on analysis of the SIRAS registry data:

You can read the original SIRAS study protocol here:


For further information about the study, you can send general enquiries to